Pipeline Strategy: Balancing Science, Feasibility, and ROI in Clinical Development Decisions What does it take to make confident, cross-functional pipeline decisions that drive approval speed and sustainable value for companies in today’s clinical research landscape? Moderated by Emily Roberts-Thomson, Development Operations Leader Featuring: • Raj Patel, Chief Operating Officer, ReacX Pharmaceuticals • Nikhil Dube, Lifecycle Management Strategy Lead, Biogen • Mukhtar Ahmed, Director, Project and Portfolio Strategy, Greenstone Biosciences Recorded live at COG Bay Area, this panel brings together senior voices from leading biotech and pharma organizations to tackle the realities of pipeline prioritization and clinical operations best practices. Moderated by Emily Roberts-Thomson, the discussion centers on actionable frameworks and leadership judgment required for effective clinical trial outsourcing, CRO selection, and cross-functional portfolio management. The panelists break down how organizations decide which programs to advance, weighing scientific potential against development feasibility, market factors, risk, and resource constraints. They candidly explore trade-offs inherent to outsourcing strategies, clinical study optimization, and how changes in ROI, timelines, or operational setbacks impact pipeline decisions. Essential listening for clinical operations leaders, outsourcing specialists, and study owners, the episode delivers practical insights on moving from scientific conviction to commercial success—and ensuring alignment across sponsors, CRO partners, and governance bodies in a rapidly shifting environment for clinical trial outsourcing. Key topics include: Balancing science, feasibility, and business drivers in pipeline advancement decisionsManaging cross-functional alignment across R&D, clinical operations, and commercial teams for better governanceThe critical role of financing, investor expectations, and real-world feasibility in CRO selection and vendor management Key Moments00:03:20 – Emily Roberts-Thomson frames the multifactor decision: “It’s never just about how good the science is. It’s about feasibility, market dynamics, and resource allocation.” 00:04:00 – Raj Patel outlines a practical pipeline selection matrix: fastest to approval, least cost, minimal risk—plus the real-world influence of boardroom priorities and investor interests. 00:05:00 – Nikhil Dube shares a three-pronged approach: scientific value, clinical development feasibility, and commercial opportunity—all critical for clinical study optimization and vendor selection frameworks. 00:06:37 – Mukhtar Ahmed describes a hybrid model leveraging academic depth and operational agility, focusing on robust human data and milestone-driven inflection points for outsourcing viability. 00:08:02 – Panel debate: How companies trade off first-in-class scientific programs against downstream commercial opportunity when making outsourcing or CRO selection decisions. 00:13:28 – Emily Roberts-Thomson and Raj Patel candidly discuss the reality of reprioritizing clinical studies based on changing business needs and operational feasibility—impacting CRO and vendor engagement. 00:14:29 – Achieving cross-functional consensus: Lessons from balancing scientific advocacy, operational feasibility, and business priorities in pipeline governance. 00:17:05 – Raj Patel on how investors and shifting market landscapes dictate which programs move forward—and how funding realities drive clinical outsourcing strategies. 00:19:13 – Nikhil Dube unpacks how project leads in large pharma orchestrate...